Articular cartilage stem cells
关节软骨干细胞
基本信息
- 批准号:8489730
- 负责人:
- 金额:$ 19.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAllograftingAreaAutologousAutologous TransplantationCartilageCell Differentiation processCell SeparationCell TherapyCell surfaceCellsChondrocytesChondrogenesisColony-Forming Units AssayDataDegenerative polyarthritisEmbryonic DevelopmentGene Expression ProfileGenetic TranscriptionGrowthHumanImmunohistochemistryInjuryMesenchymal Stem CellsMicroRNAsMorbidity - disease rateNatural regenerationPathologyPathway interactionsPhenotypePopulationProcessPropertyRNA SequencesRegulationScientistSignal PathwaySiteSorting - Cell MovementStagingStem cellsSurfaceTechniquesTechnologyTestingTissue EngineeringWorkarticular cartilagebasebonecartilage repaircell typein vitro testingin vivoinjuredjoint destructionnext generationpreventpublic health relevancerepairedstem cell populationtherapy development
项目摘要
DESCRIPTION (provided by applicant): Adult articular cartilage has been found to actually contain a small population of resident stem cells that have a restricted differentiation potential:
these cells become permanent chondrocytes when placed in exactly the same conditions under which MSCs become endochondral chondrocytes. What makes the differentiation pathway for these resident stem cells different from MSCs, and seemingly all other stem cells for which chondrogenesis has been tested? We hypothesize that the lineage restriction of articular cartilage stem cells (ACSCs) is driven by differences in RNA expression. The specific aim to test this hypothesis is to define the differences in the transcriptomes between articular cartilage
stem cells and mesenchymal stem cells and the permanent and endochondral chondrocytes they differentiate into. Next generation RNA sequencing techniques will be used to compare the transcriptomes of ACSCs and MSCs and the transcriptomes of the chondrocytes differentiated from these two stem cell types. Pathways that control the differential differentiation of ACSCs and MSCs will be identified. The analysis will include microRNAs and we aim to identify those involved in the regulation of the differentiation potential of the two stem cell types as well as permanent and endochondral chondrocyte differentiation. There are presently no markers that define the ACSC population. Although several groups have suggested cell surface markers can define ACSCs, these have not been rigorously examined. To-date, no comprehensive screen for markers has been conducted. We hypothesize that a combination of markers can be determined for the ACSC population in the manner done for other stem cell types. Surface marker array technology will be used to search for a combination of markers that can be used to define the ACSC population. Such markers can then be used to efficiently isolate permanent cartilage-producing stem cells for tissue engineering, and assess the level of stem cells in different stages of cartilage pathologies.
描述(由申请人提供):已发现成人关节软骨实际上含有少量具有有限分化潜力的常驻干细胞:
当置于与MSC成为软骨内软骨细胞完全相同的条件下时,这些细胞成为永久性软骨细胞。是什么使这些常驻干细胞的分化途径不同于MSC,以及似乎所有其他已经测试过软骨形成的干细胞?我们假设关节软骨干细胞(ACSC)的谱系限制是由RNA表达的差异驱动的。检验这一假设的具体目的是确定关节软骨之间转录组的差异,
干细胞和间充质干细胞以及它们分化成的永久性和软骨内软骨细胞。下一代RNA测序技术将用于比较ACSC和MSC的转录组以及从这两种干细胞类型分化的软骨细胞的转录组。将鉴定控制ACSC和MSC的差异分化的途径。该分析将包括microRNA,我们的目标是确定参与调节两种干细胞类型的分化潜力以及永久性和软骨内软骨细胞分化的microRNA。目前还没有定义ACSC人群的标志物。虽然有几个研究小组已经提出细胞表面标记物可以定义ACSC,但这些尚未得到严格的检查。迄今为止,尚未对标记进行全面筛查。我们假设,可以用对其他干细胞类型所做的方式来确定ACSC群体的标志物组合。将使用表面标志物阵列技术搜索可用于定义ACSC人群的标志物组合。然后,这些标记物可以用于有效地分离用于组织工程的永久性软骨产生干细胞,并评估软骨病理学不同阶段的干细胞水平。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian Johnstone其他文献
Brian Johnstone的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian Johnstone', 18)}}的其他基金
Novel antibodies for mesenchymal tissue stem cells
针对间充质组织干细胞的新型抗体
- 批准号:
7465578 - 财政年份:2007
- 资助金额:
$ 19.64万 - 项目类别:
Novel antibodies for mesenchymal tissue stem cells
针对间充质组织干细胞的新型抗体
- 批准号:
7242245 - 财政年份:2007
- 资助金额:
$ 19.64万 - 项目类别:
Aberrant collagen type II formation and metabolism
II 型胶原蛋白的异常形成和代谢
- 批准号:
6479992 - 财政年份:2001
- 资助金额:
$ 19.64万 - 项目类别:
相似海外基金
Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
- 批准号:
26462277 - 财政年份:2014
- 资助金额:
$ 19.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
- 批准号:
8344380 - 财政年份:2012
- 资助金额:
$ 19.64万 - 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
- 批准号:
7878675 - 财政年份:2009
- 资助金额:
$ 19.64万 - 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
- 批准号:
7677758 - 财政年份:2009
- 资助金额:
$ 19.64万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7466112 - 财政年份:2008
- 资助金额:
$ 19.64万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
8010394 - 财政年份:2008
- 资助金额:
$ 19.64万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
8208131 - 财政年份:2008
- 资助金额:
$ 19.64万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7575273 - 财政年份:2008
- 资助金额:
$ 19.64万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7765518 - 财政年份:2008
- 资助金额:
$ 19.64万 - 项目类别: